Education > XRAY > Prostate Cancer

FORCE's eXaming the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

1 through 10 of 37

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer

Most relevant for: People concerned about their risk of colorectal or ovarian cancer.

This study looked at the impact of daily aspirin use for lowering the risk for multiple types of cancers and whether this risk reduction can be modified by cancer risk factors such as obesity, smoking, physical inactivity or a family history of cancer. (3/19/21)

Read More
Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : FDA approves Orgovyx, the first oral hormone therapy of its type for treating advanced prostate cancer

Most relevant for: Men with advanced prostate cancer

In December 2020, the FDA approved Orgovyx to treat advanced prostate cancer. The findings were based on the HERO clinical trial of more than 900 men. Data from this trial showed the new therapy was safer than standard androgen deprivation treatment for men with advanced prostate cancer and risk of cardiovascular disease. (2/18/21)

Read More
FDA approves Orgovyx, the first oral hormone therapy of its type for treating advanced prostate cancer

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Guideline : COVID vaccines for people with cancer

Most relevant for: Cancer patients, their family and caregivers

Should cancer patients get a COVID vaccine? The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) provide guidance for people with cancer. These experts recommend that most cancer patients get vaccinated as soon as the vaccine is offered (unless they are allergic to a vaccine component). Cancer patients who have had recent surgery may delay vaccination a few days after surgery. Those with a suppressed immune system are advised to delay getting the vaccine until they’re healthy enough to do so. (2/1/21)

Read More
COVID vaccines for people with cancer

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : FDA approves new imaging drug for detecting spread of prostate cancer

Most relevant for: Men with prostate cancer

On December 1, 2020 the FDA approved a new type of imaging technology to confirm the spread of newly diagnosed prostate cancer that is suspected to be metastatic. The approval also includes use for confirming suspected recurrence in men who have rising PSA after treatment. The approval is based on two clinical trials that showed this new technique to be safe and consistent in accurately detecting cancer that has spread beyond the prostate gland. (1/7/21)

Read More
FDA approves new imaging drug for detecting spread of prostate cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : New imaging technology shows promise in detecting of spread of prostate cancer

Most relevant for: Men with high-risk prostate cancer

A new imaging technique is currently being tested to see if it can detect the spread of prostate cancer sooner than standard imaging. Two clinical trials show that the new technique can detect the spread of prostate cancer in men who are newly diagnosed and in men whose cancer returns after treatment. (10/16/20)

Read More
New imaging technology shows promise in detecting of spread of prostate cancer

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Personal Story : Coping with chemotherapy-induced hair loss

Most relevant for: People who receive chemotherapy for cancer treatment

Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)

Read More
Coping with chemotherapy-induced hair loss

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer

Most relevant for: Men with metastatic castration-resistant prostate cancer who have certain inherited or tumor mutations in DNA repair genes

The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. (6/1/20)

Read More
PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer

Topic : COVID-19 and Cancer

Most relevant for: People in treatment for cancer, or people scheduled for surgery

The current COVID-19 pandemic has led to many changes in our communities. In this XRAY review we focus on the intersection between COVID-19 and cancer: who may be immunosuppressed, coping with changes in surveillance or treatment, and evaluating and dealing with media. (4/13/20)

Este artículo está disponible en español.

Read More
COVID-19 and Cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Cancer risk associated with inherited mutations in Lynch syndrome genes

Most relevant for: People with Lynch syndrome mutations

Lynch syndrome is the most common inherited cause of cancer affecting about 1 in 300 people. People with Lynch syndrome have an increased risk of colorectal endometrial and other cancers. A large study followed people with mutations in the Lynch syndrome genes MLH1, MSH2, MSH6 and PMS2 to determine the risk of other types of cancer. (2/21/20)

Read More
Cancer risk associated with inherited mutations in Lynch syndrome genes

Relevance: High

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Supportive care can improve quality of life for people with metastatic breast cancer

Most relevant for: People diagnosed with metastatic breast cancer

Metastatic breast cancer patients have unique needs for treatment and care. Connecting patients to appropriate support services and palliative care is an area of need in health care. A recent study reported improvement in metastatic breast cancer patient quality of life and wellness with an intervention program called the Supportive, Education and Advocacy (MBC-SEA) program. (8/21/19)

Read More
Supportive care can improve quality of life for people with metastatic breast cancer

This Portal Sponsored By:

AstraZeneca